Day One Biopharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Day One Biopharmaceuticals's earnings have been declining at an average annual rate of -27.3%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-27.3%
Earnings growth rate
36.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -54.5% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Day One Pharmaceuticals: Ojemda Approval A Big Win, Current Valuation Fair
Apr 24We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 18
Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects
Feb 01We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Dec 04We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
Jun 19We're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash Wisely
Mar 08Here's Why We're Not Too Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Situation
Nov 22Day One Biopharmaceuticals: Recent Strong Data, And Major Catalysts Ahead
Sep 04Day One Biopharmaceuticals GAAP EPS of -$0.60
Aug 04Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Intrinsic Value Is Potentially 52% Above Its Share Price
Jun 18Day One Biopharmaceuticals: Early Pediatric Brain Cancer Data Makes Tentative Buy Case
Jun 15We're Not Very Worried About Day One Biopharmaceuticals' (NASDAQ:DAWN) Cash Burn Rate
Apr 29An Intrinsic Calculation For Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Suggests It's 42% Undervalued
Jan 14Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans
Dec 10Day One Biopharmaceuticals (NASDAQ:DAWN) Is In A Good Position To Deliver On Growth Plans
Aug 27Day One Biopharma draws bullish calls as quiet period ends
Jun 21Revenue & Expenses BreakdownBeta
How Day One Biopharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -189 | 76 | 131 |
| 30 Sep 23 | 0 | -175 | 70 | 119 |
| 30 Jun 23 | 0 | -166 | 69 | 108 |
| 31 Mar 23 | 0 | -157 | 67 | 98 |
| 31 Dec 22 | 0 | -142 | 61 | 86 |
| 30 Sep 22 | 0 | -124 | 55 | 71 |
| 30 Jun 22 | 0 | -105 | 47 | 59 |
| 31 Mar 22 | 0 | -183 | 38 | 46 |
| 31 Dec 21 | 0 | -171 | 29 | 44 |
| 30 Sep 21 | 0 | -183 | 20 | 37 |
| 30 Jun 21 | 0 | -167 | 12 | 29 |
| 31 Mar 21 | 0 | -54 | 7 | 21 |
| 31 Dec 20 | 0 | -41 | 5 | 9 |
Quality Earnings: DAWN is currently unprofitable.
Growing Profit Margin: DAWN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DAWN is unprofitable, and losses have increased over the past 5 years at a rate of 27.3% per year.
Accelerating Growth: Unable to compare DAWN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DAWN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: DAWN has a negative Return on Equity (-54.52%), as it is currently unprofitable.